GlobalData authored this report for a global pharmaceutical client to support their R&D decision marking process and strategies.
The client has diversified their pharmaceutical business and they have focused Women’s health, urology and internal medicine as their therapeutic focus in their R&D in recent years; however, their R&D strategies were immature and less strategic to develop a novel compounds compared with their peer competitors such as Astellas or Takeda.
Our Solution
The GlobalData team undertook a comprehensive and extensive secondary including Pharma IC and professional journal reviews and web sites across the US, Europe and Japanese market. The aim of SMR was to capture the current treatment landscape, pipeline activity, unmet medical needs in women’s health indications and urological disorder indications across 5 MM and compare the difference.
Outcome
The comprehensive and user friendly interactive prioritization model were delivered to the client. Our report covered an overview of disease, treatment landscape, unmet medical needs, and pipeline activity across 5 MM.
Our consultants work closely with you to understand requirements and develop a tailored approach and deliverables.
